• Home
  • Blog
  • Android
  • Cars
  • Gadgets
  • Gaming
  • Internet
  • Mobile
  • Sci-Fi
Tech News, Magazine & Review WordPress Theme 2017
  • Home
  • Blog
  • Android
  • Cars
  • Gadgets
  • Gaming
  • Internet
  • Mobile
  • Sci-Fi
No Result
View All Result
  • Home
  • Blog
  • Android
  • Cars
  • Gadgets
  • Gaming
  • Internet
  • Mobile
  • Sci-Fi
No Result
View All Result
Blog - Creative Collaboration
No Result
View All Result
Home Sci-Fi

Healthcare analytics platform H1 has acquired Ribbon, backed by a16Z and General Catalyst

January 8, 2025
Share on FacebookShare on Twitter

H1, a healthcare data analytics platform serving the pharmaceutical industry with data on over 10 million healthcare professionals, has acquired Ribbon, a startup that helps patients find doctors that are supported by their insurance.

Financial terms of the deal have not been disclosed. The last time that Ribbon — founded in 2016 and a Y Combinator alum — raised money was in 2021, when it closed a $43.5 million Series B that valued it at $283.5 million, per PitchBook data.

Many startups that haven’t secured funding in over three years are increasingly facing pressure, with many becoming acquisition targets or facing imminent closure. But Arial Katz, co-founder and CEO of H1, told TechCrunch that Ribbon “was not a company that was running out of business.” H1 is paying a combination of stock and cash to acquire Ribbon, which is earning “well over tens of millions in revenue,” he added.

Ribbon had raised $55 million overall from investors that include Andreessen Horowitz, General Catalyst and Rock Health.  

For its part, H1 has raised around $200 million and was last valued around $773 million in 2022. PitchBook notes it also raised an undisclosed amount in 2024.

H1 had its sights on combining with Ribbon for years, Katz told TechCrunch. The two companies collect similar information but serve different client sets, he said.

“I’ve been trying to buy Ribbon for three years,” Katz said, adding that the two companies have many synergies because they collect similar data.

Ribbon serves patients by providing details about doctors’ expertise, cost and quality. Ribbon’s data is purchased by healthcare navigation companies like Transcarent and Rightway and then is made available to patients through health insurance sites. H1 meanwhile tends to work with pharmaceutical and other companies in the healthcare business providing data and other insights to help them, for example, set up and run clinical trials.

Although Ribbon was likely not a fire sale, we expect to see many startups this year struggling to raise follow-on funding and reaching the end of their runways. They’ll become acquisition targets, if they don’t shut down altogether.

Next Post

Govee's innovative smart lighting solutions for 2025: Brighten your home and elevate your life

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

No Result
View All Result

Recent Posts

  • ALSO raises $200M Series C at $1B valuation
  • Magic The Gathering: Secrets Of Strixhaven Includes Banned Power Nine Spell And A Powerful Tutor
  • Big Spring Sale Samsung TV deals: Save on Q8F, S90F, and QN90F models
  • Save $300 on the Samsung Odyssey G9 49-Inch Curved Monitor
  • New Bluesky AI only slightly less unpopular than JD Vance

Recent Comments

    No Result
    View All Result

    Categories

    • Android
    • Cars
    • Gadgets
    • Gaming
    • Internet
    • Mobile
    • Sci-Fi
    • Home
    • Shop
    • Privacy Policy
    • Terms and Conditions

    © CC Startup, Powered by Creative Collaboration. © 2020 Creative Collaboration, LLC. All Rights Reserved.

    No Result
    View All Result
    • Home
    • Blog
    • Android
    • Cars
    • Gadgets
    • Gaming
    • Internet
    • Mobile
    • Sci-Fi

    © CC Startup, Powered by Creative Collaboration. © 2020 Creative Collaboration, LLC. All Rights Reserved.

    Get more stuff like this
    in your inbox

    Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

    Thank you for subscribing.

    Something went wrong.

    We respect your privacy and take protecting it seriously